MMRP

Metrc Expands Track-And-Trace Government Contract with the State of Missouri for Regulation of its Adult-Use Cannabis Market

Retrieved on: 
Tuesday, February 7, 2023
Third Amendment, Health, City, RFID, NIC, Cannabis, Data collection, MMRP, DHSS, Government, Software as a service, Patient, Seamless, Environment, Missouri Department of Health and Senior Services, Drug

LAKELAND, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Metrc , the most trusted and experienced provider of cannabis regulatory technology systems in the U.S., announced the expansion of its contract with the State of Missouri to support the regulation of its adult-use cannabis market.

Key Points: 
  • LAKELAND, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Metrc , the most trusted and experienced provider of cannabis regulatory technology systems in the U.S., announced the expansion of its contract with the State of Missouri to support the regulation of its adult-use cannabis market.
  • The Company has been the state’s partner in the regulation of its medical cannabis market since 2019.
  • When Amendment 3 was passed in November 2022, Missouri became the 21st state to legalize adult-use cannabis.
  • Metrc continues to be the favored partner of regulators and businesses in serving their unique needs and goals.

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Retrieved on: 
Friday, December 2, 2022
PD-1, Woman, RECIST, Safety, R, Progression-free survival, MMRP, III, European Society of Gynaecological Oncology, MSI-H, BTLA, FDA, Therapy, Inflammation, GPP, GSK, Network, Patient, MSS, Phase II, Endometrial cancer, PD-L1, Antibody, PFS, Dietary supplement, Pharmaceutical industry, EU

GSK expects to publish full results from the RUBY trial in a medical journal and present at an upcoming scientific meeting.

Key Points: 
  • GSK expects to publish full results from the RUBY trial in a medical journal and present at an upcoming scientific meeting.
  • RUBY is a two-part global, randomised, double-blind, multicentre study of patients with primary advanced or recurrent endometrial cancer.
  • RUBY is part of an international collaboration of European Network of Gynaecological Oncological Trial groups (ENGOT) and the GOG Foundation.
  • AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP.